Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
50 Huntingdon Pike
2nd Floor
Rockledge, PA 19046
Summary
- David Chen, MD, is a Urologist based in Rockledge, PA, specializing in minimally invasive surgery, surgical oncology, and trauma and reconstructive surgery. He completed his medical education at Weill Cornell Medicine, followed by residencies in surgery and urology and a fellowship in urologic surgical oncology at New York Presbyterian Hospital. A Professor of Urologic Oncology at Fox Chase Cancer Center since 2004, Dr. Chen has research interests in genitourinary cancers, including renal neoplasms and prostate cancer. His recent publications include studies on bladder cancer and prostate cancer management. He has conducted clinical trials on innovative therapies for prostate and bladder cancer. Dr. Chen is recognized as a Fellow of the American College of Surgeons and has received certification for CMS Meaningful Use Stage 1.
Education & Training
- New York Presbyterian Hospital (Columbia and Cornell Campus)Fellowship, Urologic Surgical Oncology, 2003 - 2004
- New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1999 - 2003
- New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 1997 - 1999
- Weill Cornell MedicineClass of 1997
- National Cancer InstituteHHMI-NIH Research Scholar, Urologic Oncology, 1994 - 1996
Certifications & Licensure
- PA State Medical License 2004 - 2026
- NJ State Medical License 2021 - 2025
- NY State Medical License 1998 - 2004
- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACS) American College of Surgeons
Clinical Trials
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
- Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma Start of enrollment: 2012 Nov 01
- Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) Start of enrollment: 2013 Mar 18
- Join now to see all
Publications & Presentations
PubMed
- A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery.Nestor F Esnaola, Raju Chelluri, Jason Castellanos, Ariella Altman, David Y T Chen
Annals of Surgery. 2025-03-01 - Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).Daniel M Geynisman, Philip H Abbosh, Eric Ross, Matthew R Zibelman, Pooja Ghatalia
Journal of Clinical Oncology. 2024-12-16 - 2 citationsComparison of perioperative and subacute postoperative complications between LDR and HDR monotherapy brachytherapy for prostate cancer.Peter L Lee, Karen Ruth, Douglas Y Lee, Mark A Hallman, David Y T Chen
Brachytherapy. 2024-07-26
Authored Content
- Innovative Transperineal Biopsy TechniqueJanuary 2018
Committees
- Member, SUO Fellowship Committee 2023 - Present
Professional Memberships
- Member
- Member
External Links
- Web profilehttps://www.foxchase.org/david-chen
- Fellowship programhttps://www.foxchase.org/research/education/clinical-training-programs/fellowships/urologic-oncology-fellowship
- Googlehttps://goo.gl/fSBgrj
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: